Huiliao Biotech Completes Nearly 100 Million Yuan Series A Initial Closing, Accelerating Innovation and Development of mRNA Technology Platform

On January 14, 2025, Suzhou HuiLiao Biomedical Technology Co., Ltd. announced the completion of the first close of its Series A financing round, raising nearly 100 million yuan. The round was led by China Capital and followed by Nanjing Vazyme Biotech Co., Ltd.

This financing round recognizes HuiLiao's global leadership in the mRNA product pipeline for animal health and affirms its mRNA drug technology platform and industrial-scale production capabilities. The funds will be used to advance the company's product pipeline, build industrialization infrastructure, and promote commercialization. Additionally, the financing will support HuiLiao in achieving clinical trials and future commercial launch of its first veterinary mRNA vaccine, providing cost-effective and high-performance disease prevention and control solutions for the livestock industry.

Suzhou HuiLiao Biomedical Technology Co., Ltd., founded in 2021 and headquartered in Suzhou Industrial Park, is a leading enterprise in Suzhou, a unicorn cultivation enterprise, and a recipient of provincial-level science and technology projects. The company also serves as the Vice President unit of the Nucleic Acid Drug Branch of the China Veterinary Drug Association. HuiLiao has established a globally leading, independently developed CLS/LNP "dual-wheel" delivery system platform, an mRNA design platform, and a production process platform. Based on this platform, the company has developed a series of vaccines for infectious diseases, cancer vaccines, cell therapies, and protein replacement drugs.

In 2024, significant breakthroughs were made in the development of mRNA vaccines for Porcine Epidemic Diarrhea Virus (PEDV) and Porcine Deltacoronavirus (PDCoV), with related achievements published in top international journals. Furthermore, several mRNA vaccines for livestock developed by the company have been validated through animal trials by multiple end-users, and groundbreaking progress has been achieved in pet mRNA vaccines.

For this round of financing, Dr. Zhong Tianyi, Founder & CEO of the company, stated:

"We sincerely thank the many outstanding investors in the industry for their deep recognition and strong support, and we are especially grateful for the relentless efforts of all team members. It is your trust and support that enable us to set sail in the challenging yet opportunity-rich blue ocean of biopharmaceuticals. HuiLiao Bio is committed to technological innovation and industrialization in the mRNA field, providing better options for human and animal health, and addressing unmet clinical and market needs. With this round of financing, we look forward to accelerating the clinical development and industrialization of our product pipeline, aiming to become a globally competitive leader in the mRNA field. We warmly welcome outstanding talents at all levels in the industry to join HuiLiao Bio and together create a brilliant future."

China Capital stated:

"The mRNA drug field has demonstrated broad application prospects. With its leading technology, HuiLiao Bio has become a global leader in novel animal vaccine products. The self-developed delivery system of HuiLiao Bio has broken through the 'bottleneck' patent barriers in the mRNA drug field and is leading the industry in multiple pipelines. Currently, HuiLiao Bio's veterinary mRNA vaccine is about to enter the IND stage. China Capital is willing to support the development of innovative domestic pharmaceutical companies like HuiLiao Bio in the long term, leveraging internationally leading innovative technologies to address clinical and market needs, and contributing to the healthy development of humans and animals."

Novozan stated:

"Through long-term cooperation with HuiLiao Bio, we highly recognize its innovation and market competitiveness. As a leader in the mRNA vaccine field, HuiLiao Bio not only possesses a top-tier nucleic acid drug research and production platform but also leads industry development with its forward-looking vision. We are pleased to support HuiLiao Bio and work together to provide cost-optimized innovative veterinary mRNA vaccine solutions for agricultural development, committed to successfully bringing advanced vaccine products to the global market, enhancing the profitability of livestock industry customers, and promoting high-quality development in the pet industry."

About Guozhong Capital

Founded in December 2015, Guozhong Capital is a fund management platform specializing in venture capital founded by Dr. Shi Anping and some core teams of the former Shenzhen Venture Capital Group. The fund has a cumulative management fund of RMB 16 billion, which consists of three entity funds of the National SME Development Fund and a direct investment sub-fund of the National Green Development Fund, and is the first management institution in China to continuously manage three entity funds of the National SME Development Fund.

Guozhong Capital advocates the investment philosophy of research first, investment and research, guides investment through in-depth research on the industrial chain, focuses on investment opportunities in strategic emerging industries, and focuses on outstanding enterprises in the fields of medical health, green and low-carbon and new energy vehicles, semiconductors and electronic information, new materials and advanced manufacturing, AI+ and embodied intelligence, new display and intelligent terminals. By the end of 2024, Guozhong Capital has invested in more than 210 enterprises, with an investment amount of nearly 8 billion yuan, and has formed a relatively complete layout in multiple industrial chains such as new energy vehicles, intelligent driving, semiconductors and electronic components, biomedicine and health, new display technology, robots, and carbon fiber composite materials.

About Novezan

Novozan is a biotechnology company that conducts technology research and development and product development around enzymes, antigens, antibodies and other functional proteins and polymer organic materials. Relying on the self-established key common technology platform, it has successively entered the business fields of life science, in vitro diagnostics, biomedicine, etc., and is one of the few R&D and innovative enterprises in China that has both independent and controllable upstream technology development capabilities and terminal product production capacity, and is committed to intelligently manufacturing "biochips" and continues to inject new vitality into the development of the biotechnology industry.

About Suzhou Huiliao

Suzhou Huiliao Biotechnology is a high-tech enterprise engaged in the comprehensive provision of nucleic acid drug industrialization. The company's business spans the research and production of mRNA drugs, clinical trial design, data analysis, and other areas, with a focus on the development of mRNA technology-based infectious disease vaccines, cancer vaccines, cell therapies, protein replacements, and more.